AC Immune SA (ACIU) AI Stock Analysis

• Market Cap: $154.35M
• Dividend Yield: N/A
• Average Volume (3M): 207.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 88.63%
• EPS Growth: 18.78%
• Country: US
• Employees: 133
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 98,943,130
• 10 Day Avg. Volume: 224,751
• 30 Day Avg. Volume: 207,651
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 12.59
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $16.00
• Price Target Upside: 925.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

ACIU's overall score reflects the company's financial potential, with positive cash flow trends and stable equity. However, persistent net losses and bearish technical indicators present significant challenges. The stock's valuation is unattractive due to a negative P/E ratio and lack of dividend yield, indicating limited appeal to value investors. Continuous improvement in profitability and technical conditions could enhance the stock's outlook.

Positive Factors

Clinical Trial Data

AC Immune announced positive additional interim and safety data from the Phase 2 VacSYn trial for ACI-7104, showing significant increases in anti-alpha-syn antibodies.

Financial Stability

The company ended 4Q24 with CHF 166M in cash, which should provide cash runway into 1Q27.

Safety Profile

The vaccine continues to be safe, with repeated immunization resulting in antibody boosting and amplification of the response.

Negative Factors

Product Pipeline Timeline

The selection of lead candidates for Morphomer Tau and Morphomer alpha-syn (small molecule aggregation inhibitors programs) is expected in 2025.

Regulatory Milestones

The company is expecting several interesting datapoints in 2025, including additional interim data from Part 2 of the Phase 2 VacSYn trial of ACI-7104.056 (anti-alpha-syn vaccine) in Parkinson’s disease.

AC Immune SA Business Overview & Revenue Model

Company Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

How the Company Makes Money

AC Immune SA generates revenue primarily through collaboration and licensing agreements with major pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of certain developmental or regulatory milestones, and royalties on future sales of products developed from the collaborations. The company's innovative platforms and extensive research and development efforts attract significant investment and partnership opportunities, contributing to its income streams. Additionally, AC Immune may receive funding and grants for its research initiatives, further supporting its financial model.

AC Immune SA Financial Statement Overview

Summary

AC Immune SA shows potential with increasing revenues and efficient cash flow management in the latest period, though profitability remains a challenge. The balance sheet is stable, with a strong equity position. Operational and financial volatility may pose risks, requiring a focus on leveraging positive cash flow trends to ensure long-term viability.

Income Statement

The company's revenue has shown significant volatility, with revenue increasing from 2022 to 2024. However, profitability remains a concern with negative net income and EBIT margins. The gross profit margin is positive in 2024, indicating some operational efficiency improvement, but net losses persist.

Balance Sheet

AC Immune SA maintains a strong equity base relative to its assets, with a manageable debt-to-equity ratio. However, the company has been accumulating net losses, affecting its return on equity. The equity ratio is healthy, indicating stability in capital structure.

Cash Flow

The cash flow situation shows improvement with a large positive free cash flow in 2024, albeit following a negative trend in prior years. The operating cash flow to net income ratio reflects better cash management, though sustainability remains a question due to historical volatility.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
27.31M	14.80M	3.94M	0.00	15.43M
	Gross Profit
27.31M	-39.80M	-56.40M	-62.28M	-44.06M
	EBIT
-52.38M	-53.62M	-70.85M	-79.01M	-61.26M
	EBITDA
-48.62M	-51.83M	-69.05M	-77.11M	-61.26M
	Net Income Common Stockholders
-50.92M	-54.23M	-70.75M	-73.00M	-62.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
165.49M	103.05M	122.59M	198.22M	225.89M
	Total Assets
230.91M	182.81M	185.94M	261.44M	238.74M
	Total Debt
5.43M	3.50M	2.80M	2.91M	2.22M
	Net Debt
-30.85M	-75.00M	-28.79M	-79.31M	-158.67M
	Total Liabilities
118.64M	22.17M	16.95M	29.46M	23.26M
	Stockholders Equity
112.27M	160.64M	168.99M	231.98M	215.48M
Cash Flow		Free Cash Flow
65.27M	-61.21M	-74.81M	-68.32M	-61.22M
	Operating Cash Flow
65.84M	-60.41M	-73.57M	-65.69M	-59.52M
	Investing Cash Flow
-105.29M	65.64M	23.76M	-53.66M	28.33M
	Financing Cash Flow
-1.12M	43.25M	-1.35M	40.75M	-803.00K

AC Immune SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 2.28, and below the 200-day MA of 3.01, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 23.14 is Positive, neither overbought nor oversold. The STOCH value of 6.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACIU.

AC Immune SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$753.67M	―	-37.72%	―	―	-3.08%
AXSM	51 Neutral	$4.78B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
ACIU	48 Neutral	$154.35M	―	-36.38%	―	88.63%	18.78%
PRTA	47 Neutral	$550.11M	―	-23.34%	―	47.92%	17.84%
SAVA	42 Neutral	$61.35M	―	-17.19%	―	―	81.00%
ANVS	38 Underperform	$25.33M	―	-3159.09%	―	―	68.75%